Clinical trials: Small Cell Lung Cancer ( SCLC )
Lung Cancer, Small Cell
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access.
- Trial name
- SCOT (NCT00997061)
- Testing
- HYCAMTIN
- Where
- 61 sites in Austria, Czechia and 12 more
- Volunteers
- 500 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 203 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
- Trial name
- NCT01951157
- Testing
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00034346
- Testing
- ABX-EGF, paclitaxel, carboplatin
- Volunteers
- 194 people
- Sponsor
- Amgen
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
- Trial name
- NCT04303780
- Testing
- AMG 510, Docetaxel
- Where
- 274 sites in United States, Australia and 21 more
- Volunteers
- 345 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)
The main purpose of this randomized phase II trial is to evaluate the clinical feasibility and activity of administering adjuvant chemotherapy of pemetrexed/carboplatin compared with vinorelbine/carboplatin in patients with…
- Trial name
- NCT01258127
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Shanghai Nancy Medical Sci-Tech Co. Ltd
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
This randomised, controlled, open-label, prospective trial is designed to assess the efficacy and safety of icotinib maintenance therapy after sequential Icotinib plus chemotherapy versus Icotinib maintenance therapy after…
- Trial name
- NCT02194556
- Testing
- Sequential and maintenance icotinib, Maintenance icotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Cachexia, NSCLC
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia
SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02515032
- Testing
- Nutrifriend Cachexia
- Where
- 14 sites in Croatia, Italy and 2 more
- Volunteers
- 56 people
- Sponsor
- Smartfish AS
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after…
- Trial name
- NCT00932893
- Testing
- PF-02341066, Pemetrexed, Docetaxel
- Where
- 264 sites in United States, Australia and 20 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
- Trial name
- NCT00051493
- Testing
- ALIMTA, Carboplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Advanced Non-small Cell Lung Cancer (NSCLC)
AMT-116 in Combination With AK112 in Patients With Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT07590531
- Testing
- AMT-116, AK112
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Multitude Therapeutics Inc.
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Metastatic Non-Small Cell Lung Cancer
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and…
- Trial name
- NCT04599712
- Testing
- Amivantamab
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.